IPOPLUS

₹1,368.3

▲ +16.7 +1.24%

18 Jun 2026

NSE Listed · Pharmaceuticals

Rubicon Research Limited (RUBICON)

Volume: 33,385Avg Vol 1W: 35,103Avg Vol 1M: 64,73252W Range:₹570.75₹1,400
NSE BSE
₹1,368.3▲ 1.24%
Key Ratios
Updated just now
Market Cap₹21,324 Cr
Current Price₹1,368.3
Previous Close₹1,351.6
High / Low (52w)₹1,400 / ₹570.75
Volume33,385
Avg Vol (1W)35,103
Avg Vol (1M)64,732
Stock P/E—
Book Value₹78.06
Dividend Yield0.12%
ROE19.14%
ROA10.6%
Revenue (TTM)—
Revenue Growth50.4%
Profit Margin14.07%
Total Debt₹64 Cr
Shares Outstanding16 Cr
Face Value₹1
EPS (TTM)₹4.68
P/B17.21
Debt / Equity0.24
50 DMA₹1,032.51
200 DMA₹823.75
Day change+1.24%
Price Chart
₹1,368.3▲ 118.07% · 1Y
₹1368₹5742.5Cr
2025-10-16
2026-06-16

20-day avg volume: 70K shares

Pros
  • Healthy return on equity of 19.1%.
  • Company is almost debt-free.
  • Revenue grew 49% YoY.
  • Net profit is growing year over year.
Quarterly Results
MetricMar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue₹514 Cr₹476 Cr₹412 Cr₹352 Cr₹358 Cr₹313 Cr₹296 Cr
EBITDA₹109 Cr₹100 Cr₹83 Cr₹70 Cr₹63 Cr₹61 Cr₹56 Cr
Net Profit₹77 Cr₹73 Cr₹54 Cr₹43 Cr₹36 Cr₹38 Cr₹34 Cr
EPS4.64.413.472.792.342.462.23
Profit & Loss (Annual)
MetricMar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
Revenue₹1,296 Cr₹872 Cr₹419 Cr₹330 Cr₹325 Cr₹281 Cr
EBITDA₹231 Cr₹134 Cr₹8 Cr₹-56 Cr₹72 Cr₹80 Cr
Net Profit₹134 Cr₹91 Cr₹-17 Cr₹-67 Cr₹31 Cr₹49 Cr
EPS8.685.91-1.11-4.4160.0496.68
Balance Sheet
MetricMar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
Total Assets₹1,451 Cr₹1,109 Cr₹750 Cr₹560 Cr₹538 Cr₹430 Cr
Total Liabilities₹910 Cr₹724 Cr₹463 Cr₹254 Cr₹164 Cr₹90 Cr
Equity₹541 Cr₹385 Cr₹286 Cr₹305 Cr₹374 Cr₹341 Cr
Total Debt₹64 Cr₹93 Cr₹97 Cr₹64 Cr₹38 Cr₹4 Cr
Cash Flow
MetricMar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
Operating₹198 Cr₹39 Cr₹-73 Cr₹-54 Cr₹95 Cr₹32 Cr
Investing₹-65 Cr₹-69 Cr₹-34 Cr₹-55 Cr₹-46 Cr₹-84 Cr
Financing₹-40 Cr₹44 Cr₹123 Cr₹63 Cr₹52 Cr₹80 Cr
Free Cash Flow₹128 Cr₹-17 Cr₹-117 Cr₹-109 Cr₹24 Cr₹-27 Cr
Shareholding
Promoter 59.86% Institutions 17.55% Public 22.58%

Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search